首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2016年 10期 肝病免疫和自身免疫性肝病 => 其他 =>强肝胶囊对非酒精性脂..
强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响
Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease
文章发布日期:2016年09月07日  来源:  作者:欧强,徐燕华,曲立娟,等  点击次数:1225次  下载次数:201次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的观察强肝胶囊对非酒精性脂肪性肝病(NAFLD)患者肝纤维化评分和胰岛素抵抗指数的影响。方法选取2014年8月-2015年7月在上海市第八人民医院就诊的NAFLD患者85例,随机分为治疗组(n=45)和对照组(n=40)。治疗组给予强肝胶囊,对照组给予多烯磷脂酰胆碱胶囊,2组疗程均为24周。观察2组治疗前后血清转氨酶(AST、ALT)、稳态模型胰岛素抵抗指数(HOMA-IR)以及NAFLD肝纤维化评分(NAFLDFS)的变化。计量资料组间比较采用成组t检验,组内治疗前后比较采用配对t检验;计数资料组间比较采用χ2检验。结果2组治疗后ALT、AST水平均较同组治疗前明显改善,差异均有统计学意义(P值均<0.05);与治疗前比,治疗组HOMA-IR、NAFLDFS治疗后均明显下降,差异均有统计学意义(358±085 vs 248±078,t=640,P<005;-178±124 vs -235±098,t=240,P<005)。2组间治疗后比较,治疗组HOMA-IR、NAFLDFS较对照组显著下降,差异均有统计学意义(248±078 vs 309±089,t=336,P<001;-235±098 vs -148±108,t=380,P<001)。整个疗程未见明显不良反应。结论强肝胶囊不仅能降低血清转氨酶水平,还可改善胰岛素抵抗和减轻NAFLD患者肝纤维化程度。
【Abstract】:ObjectiveTo investigate the effect of Qianggan capsules on liver fibrosis score and insulin resistance index in patients with nonalcoholic fatty liver disease (NAFLD). MethodsA total of 85 NAFLD patients who were treated in the Eighth People′s Hospital of Shanghai from August 2014 to July 2015 were enrolled and randomly divided into treatment group (45 patients) and control group (40 patients). The patients in the treatment group were given Qianggan capsules, and those in the control group were given polyene phosphatidylcholine capsules. The course of treatment was 24 weeks for both groups. The changes in serum aminotransferases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], homeostasis model assessment of insulin resistance (HOMA-IR), and NAFLD fibrosis score (NAFLDFS) after treatment were observed in both groups. The t-test was used for comparison of continuous data between groups, before-after comparison within each group was made by paired t-test; and the chi-square test was used for comparison of categorical data between groups. ResultsBoth groups showed significant improvements in ALT and AST levels after treatment (all P<001). After treatment the treatment group showed significant reductions in HOMA-IR and NAFLDFS (358±085 vs 248±078,t=640,P<001; -178±124 vs -235±098,t=240,P<001) and the treatment group had significantly lower HOMA-IR and NAFLDFS than the control group(1248±078 vs 309±089,t=336,P<001;-235±098 vs -148±108,t=380,P<001). No serious adverse events were observed during the course of treatment. ConclusionQianggan capsules not only reduce the levels of serum aminotransferases, but also improve insulin resistance and reduce fibrosis degree in NAFLD patients.
【关键字】:脂肪肝; 强肝胶囊; 胰岛素抗药性; 肝纤维化评分
【Key words】:fatty liver; Qianggan capusule; insulin resistance; nonalcoholic fatty liver disease fibrosis score
【引证本文】:欧强, 徐燕华, 曲立娟, 等. 强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响[J]. 临床肝胆病杂志, 2016, 32(10): 1951-1954.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号